{"id":48040,"date":"2020-07-16T17:00:05","date_gmt":"2020-07-16T16:00:05","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=48040"},"modified":"2020-07-17T15:39:01","modified_gmt":"2020-07-17T14:39:01","slug":"a-call-for-a-peoples-vaccine","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/","title":{"rendered":"A call for a people&#8217;s vaccine"},"content":{"rendered":"<p><span style=\"font-weight: 400\">Recently, the US government bought virtually all <\/span><a href=\"https:\/\/www.theguardian.com\/us-news\/2020\/jun\/30\/us-buys-up-world-stock-of-key-covid-19-drug.\"><span style=\"font-weight: 400\">remdesivir<\/span><\/a><span style=\"font-weight: 400\"> supplies for the next three months from US pharmaceuticals company Gilead, following recent results which showed that the drug might shorten recovery times for covid-19 patients. This is hugely problematic for two reasons. Firstly, it denies the rest of the world this treatment. Secondly, the high price charged by Gilead\u2014estimated at <\/span><a href=\"https:\/\/theconversation.com\/the-us-has-bought-most-of-the-worlds-remdesivir-heres-what-it-means-for-the-rest-of-us-141791\"><span style=\"font-weight: 400\">over 500 times its production cost<\/span><\/a><span style=\"font-weight: 400\">, despite receiving an <a href=\"https:\/\/theconversation.com\/the-us-has-bought-most-of-the-worlds-remdesivir-heres-what-it-means-for-the-rest-of-us-141791\">estimated US$70.5 million<\/a> in public development funding\u2014provides a stark reminder that the current system leaves all the power in the hands of pharmaceutical companies to decide who gets the medicines they need and who does not.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">As people around the world pin their hopes on a vaccine to put an end to this pandemic, big pharmaceutical companies continue to issue promises on fair, equitable access. Yet the case of remdesivir is just the latest example of why, when the stakes are so high, this does not always happen.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Consider HIV\/AIDS. In 1996, a treatment for HIV\/AIDS was developed and priced at <\/span><a href=\"https:\/\/www.theguardian.com\/commentisfree\/2020\/apr\/15\/coronavirus-treatment-drug-companies\"><span style=\"font-weight: 400\">\u00a36500 per person<\/span><\/a><span style=\"font-weight: 400\">. Despite the determination of HIV\/AIDS campaigners, it <a href=\"https:\/\/podcasts.apple.com\/gb\/podcast\/why-we-need-peoplesvaccine-achal-prabhala-mohga-kamal\/id1480735096?i=1000476322245\">took eight years<\/a>\u2014<\/span><span style=\"font-weight: 400\">and many millions of unnecessary deaths\u2014before the treatment was made available at prices that were affordable for people in countries such as South Africa and India.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Nor are the outrages only historical. Pneumonia currently kills over 2000 children under the age of 5 every day. That\u2019s one child\u2019s life lost every 39 seconds. But a vaccine was found 40 years ago. For the last 20 years patent owners Pfizer and GlaxoSmithKline have kept prices high, leaving millions of children unable to access it. They are estimated to have made <a href=\"https:\/\/www.ft.com\/content\/93374f4a-e538-11e5-a09b-1f8b0d268c39\">billions of pounds in profit<\/a>.<\/span><\/p>\n<p><span style=\"font-weight: 400\">If governments are serious about combatting coronavirus and ensuring access for all, then there is a solution\u2014a people\u2019s vaccine. A vaccine that is patent free, with mandatory worldwide sharing of all covid-19 related knowledge and intellectual property, a commitment to transfer the technology, and to urgently build much needed extra manufacturing capacity. This would hasten development of a vaccine and maximize its supply. Provided at transparent cost price, without profit, free of charge to people, across the world.<\/span><\/p>\n<p><span style=\"font-weight: 400\"><a href=\"https:\/\/www.unaids.org\/en\/resources\/presscentre\/featurestories\/2020\/may\/20200514_covid19-vaccine-open-letter\">Over 150 current and former world leaders, experts, and economists have given their backing to the idea<\/a>.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">The <\/span><a href=\"https:\/\/www.who.int\/news-room\/detail\/29-05-2020-international-community-rallies-to-support-open-research-and-science-to-fight-covid-19\"><span style=\"font-weight: 400\">World Health Organization (WHO) and Costa Rica<\/span><\/a><span style=\"font-weight: 400\"> recently launched a voluntary scheme to share knowledge, data, and intellectual property for vaccines and treatments for the coronavirus, which is a major step in the right direction. It is supported by several governments, including Portugal and the Netherlands.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">The primary barrier standing in the way of delivering a vaccine to all is allowing big pharma companies to continue putting their exclusive patents and profits first. There is no justification for intellectual property rationing supply of this global public good. Mandatory global sharing of the knowledge, data, and intellectual property would remove the need for today\u2019s unnecessary and expensive bidding war between rich governments to secure preferential access.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Let\u2019s not forget, taxpayers are already providing the lion\u2019s share of funding for research and development into a vaccine. Public money is bearing the risk of innovation. Approximately <\/span><a href=\"https:\/\/www.democracynow.org\/2020\/5\/7\/remdesivir_gilead_achal_prabhala\"><span style=\"font-weight: 400\">75% of all funding that has been pledged by rich countries and institutions<\/span><\/a><span style=\"font-weight: 400\"> has gone to private corporations. Governments urgently need to act and the least they could do is to make funding conditional on ensuring a vaccine is patent free and available to all.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Currently hopes are pinned on a model which relies on initiatives such as The Global Alliance for Vaccines and Immunizations (GAVI). GAVI\u2019s laudable aim is to improve vaccine access in poor countries, but crucially it does not challenge the model of pharmaceutical monopoly responsible for inequality of access in the first place.<\/span><\/p>\n<p><span style=\"font-weight: 400\">GAVI spend billions of development aid buying expensive vaccines for poor countries when those vaccines could have been much cheaper. Their charity also doesn\u2019t extend to billions of people in middle income countries where vaccines are too often unaffordable.\u00a0\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Governments, global institutions, and the pharma industry must make the right choice. Though history provides us painful lessons, there <\/span><i><span style=\"font-weight: 400\">is<\/span><\/i><span style=\"font-weight: 400\"> inspirational precedent. Jonas Salk, the inventor of the polio vaccine was asked 65 years ago who owned the patent on his vaccine. He said: &#8220;The people. There is no patent. Could you patent the sun?&#8221;\u00a0<\/span><\/p>\n<p><em><strong>Anna Marriott<\/strong>, Oxfam GB health policy adviser. She is the lead for Oxfam&#8217;s health policy work internationally. She has written and published a number of reports on Oxfam&#8217;s focus areas of healthcare financing and delivery. Her Twitter handle is @Anna_Marriott<\/em><\/p>\n<p><em><strong>Nabil Ahmed<\/strong>, Oxfam international head of executive strategy. Nabil works on inequality strategy for Oxfam internationally and co-hosts the Equals inequality podcast. His Twitter handle is @NabslMA<\/em><\/p>\n<p><span style=\"font-weight: 400\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recently, the US government bought virtually all remdesivir supplies for the next three months from US pharmaceuticals company Gilead, following recent results which showed that the drug might shorten recovery [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/\">More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":47365,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[263],"tags":[],"class_list":["post-48040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-global-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A call for a people&#039;s vaccine - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A call for a people&#039;s vaccine - The BMJ\" \/>\n<meta property=\"og:description\" content=\"Recently, the US government bought virtually all remdesivir supplies for the next three months from US pharmaceuticals company Gilead, following recent results which showed that the drug might shorten recovery [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-16T16:00:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-07-17T14:39:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/04\/coronavirus_vaccine.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"341\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"A call for a people&#8217;s vaccine\",\"datePublished\":\"2020-07-16T16:00:05+00:00\",\"dateModified\":\"2020-07-17T14:39:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/\"},\"wordCount\":787,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/04\\\/coronavirus_vaccine.jpg\",\"articleSection\":[\"Global health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/\",\"name\":\"A call for a people's vaccine - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/04\\\/coronavirus_vaccine.jpg\",\"datePublished\":\"2020-07-16T16:00:05+00:00\",\"dateModified\":\"2020-07-17T14:39:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/04\\\/coronavirus_vaccine.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2020\\\/04\\\/coronavirus_vaccine.jpg\",\"width\":512,\"height\":341,\"caption\":\"(200414) -- BEIJING, April 14, 2020 (Xinhua) -- A staff member tests samples of the COVID-19 inactivated vaccine at a laboratory of Sinovac Biotech Ltd., in Beijing, capital of China, March 16, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates were developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm), and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started. (Xinhua\\\/Zhang Yuwei)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2020\\\/07\\\/16\\\/a-call-for-a-peoples-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A call for a people&#8217;s vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A call for a people's vaccine - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"A call for a people's vaccine - The BMJ","og_description":"Recently, the US government bought virtually all remdesivir supplies for the next three months from US pharmaceuticals company Gilead, following recent results which showed that the drug might shorten recovery [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2020-07-16T16:00:05+00:00","article_modified_time":"2020-07-17T14:39:01+00:00","og_image":[{"width":512,"height":341,"url":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/04\/coronavirus_vaccine.jpg","type":"image\/jpeg"}],"author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"A call for a people&#8217;s vaccine","datePublished":"2020-07-16T16:00:05+00:00","dateModified":"2020-07-17T14:39:01+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/"},"wordCount":787,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/04\/coronavirus_vaccine.jpg","articleSection":["Global health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/","url":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/","name":"A call for a people's vaccine - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/04\/coronavirus_vaccine.jpg","datePublished":"2020-07-16T16:00:05+00:00","dateModified":"2020-07-17T14:39:01+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/04\/coronavirus_vaccine.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2020\/04\/coronavirus_vaccine.jpg","width":512,"height":341,"caption":"(200414) -- BEIJING, April 14, 2020 (Xinhua) -- A staff member tests samples of the COVID-19 inactivated vaccine at a laboratory of Sinovac Biotech Ltd., in Beijing, capital of China, March 16, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates were developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm), and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started. (Xinhua\/Zhang Yuwei)"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2020\/07\/16\/a-call-for-a-peoples-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"A call for a people&#8217;s vaccine"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/48040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=48040"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/48040\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media\/47365"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=48040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=48040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=48040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}